Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $80.22M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.66M
Average 0.75M
Returns on capital
Nkarta, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.3%
avg -13.6%
ROIC
-31.2%
avg -28.3%
ROA
-25.8%
avg -25.9%
Analysis
ROA is currently the strongest return metric at -25.8% versus its period average of -25.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Paul J. Hastings | Chief Executive Officer & Director | USD 1.03M | 66 | 390.25K | 0.55% |
Nadir Mahmood | President and Principal Accounting & Financial Officer | USD 806.36K | 46 | 167.73K | 0.23% |
Shawn Rose | Chief Medical Officer and Head of Research & Development | USD 515.47K | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$70,421.61
Net Transaction Value
−$70,421.61
Net selling
Most Active
HASTINGS PAUL J
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 18, 26Jun 18, 2026 | HASTINGS PAUL J Direct | Sell | $4.8K$4,812.96 |
| Jan 15, 26Jan 15, 2026 | HASTINGS PAUL J Direct | Sell | $53.9K$53,915.22 |
| Jan 15, 26Jan 15, 2026 | Mahmood Nadir Direct | Sell | $11.7K$11,693.43 |
Summary
Insiders reported 0 buys worth $0.00 and 3 sells worth $70,421.61 over the last 12 months. That adds up to net selling of $70,421.61. HASTINGS PAUL J was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Nkarta, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NKTX's management, answered from reported figures.
Who manages NKTX?
Nkarta, Inc. (NKTX) lists 3 active executives. The top listed executive is Shawn Rose, Chief Medical Officer and Head of Research & Development.
Are NKTX insiders buying or selling?
Recent insider activity shows net buying of $115.09M.
Continue the stock analysis
Jump to another research area for this company.